Conformis, Inc. Announces Settlement of Medacta Patent Litigation

Rhea-AI Summary

Conformis Settles Medacta Litigation

Conformis, Inc. (NASDAQ:CFMS) announced the settlement of patent disputes with Medacta USA and its affiliates. The settlement grants Medacta a non-exclusive license to certain Conformis patents concerning patient-specific instruments for knee and shoulder implants. CEO Mark Augusti emphasized the resolution protects their patient-specific products and highlights the value of personalized surgical planning.

Positive

• Settlement of patent disputes with Medacta eliminates ongoing litigation risks.
• Non-exclusive license granted to Medacta may generate future revenue from licensing.
• Affirmation of the value of patient-specific surgical solutions enhances market position.

Negative

• None.

Conformis Settles Medacta Litigation Related to Patient-Specific Instruments

BILLERICA, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a settlement and license agreement with Medacta USA, Medacta Germany GmbH, and Medacta International SA (together, “Medacta”) that resolves all patent disputes between the companies.  

“We are pleased to have resolved all of the ongoing patent litigation related to the Medacta dispute,” said Mark Augusti, President and Chief Executive Officer. “Through this settlement, we have once again monetized our patient-specific instrument patents and steadfastly protected our patient-specific implant products and services.  Yet again, this highlights the value of providing surgeons with the ability to incorporate patient-specific surgical planning into their procedures.”

Under the terms of the settlement, Medacta will receive a non-exclusive license to certain Conformis patents related to patient-specific instrumentation for use with off-the-shelf knee and shoulder implants.

About Conformis, Inc.

Founded in 2004, Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program, as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments.  Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com.  To receive future releases in e-mail alerts, sign up at ir.conformis.com.

CONTACT:
Investor Contact
ir@conformis.com 
+1 (781) 374-5598

FAQ

What was the outcome of the Conformis and Medacta litigation?

Conformis has settled the patent disputes with Medacta, resolving all ongoing litigation.

What does the settlement involve for Medacta?

Medacta received a non-exclusive license to certain Conformis patents related to patient-specific instruments.

How does the settlement affect Conformis's business?

The settlement mitigates litigation risks and potentially opens new revenue streams through licensing.

What is the stock symbol for Conformis?

The stock symbol for Conformis is CFMS.